左乙拉西坦在癫痫老年和非常老年患者中的临床药代动力学。
Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy.
机构信息
UOC Clinica Neurologica, IRCCS Istituto delle Scienze Neurologiche, [corrected] Department of Neurological Sciences, University of Bologna, Via Foscolo 7, 40123 Bologna, Italy.
出版信息
Epilepsy Res. 2012 Feb;98(2-3):130-4. doi: 10.1016/j.eplepsyres.2011.08.020. Epub 2011 Sep 25.
We aimed to compare apparent steady-state oral clearance (CL/F) of the antiepileptic drug levetiracetam (LEV) in elderly (66-80 years, n=105) and very elderly (81-96 years, n=70) vs nonelderly (30-65 years, n=97) patients with epilepsy. Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001). LEV CL/F significantly declines with aging, elderly and very elderly patients requiring an about 30% and 50% lower dose, respectively, compared to nonelderly adults to achieve a given LEV plasma concentration.
我们旨在比较抗癫痫药左乙拉西坦（LEV）在老年（66-80 岁，n=105）和非常老年（81-96 岁，n=70）与非老年（30-65 岁，n=97）癫痫患者中的表观稳态口服清除率（CL/F）。经体重校正的中位 CL/F（mLmin(-1)kg(-1)）从 1.23（非老年）降至 0.83（老年）和 0.59（非常老年）（p<0.001）。LEV CL/F 随年龄增长显著下降，与非老年成年人相比，老年和非常老年患者分别需要大约 30%和 50%的较低剂量，以达到给定的 LEV 血浆浓度。
Zotero 插件